Archive | Next Phase Archive RSS feed for this section

Timing and Relationship: The Key to Compelling Investor Mandates

8 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

As the life science arena shifts, so do investment and licensing mandates and the technologies that investors and strategic partners seek. Life Science Nation (LSN) is known for its curated partnering database for fundraising early-stage companies across the silos of drugs, devices, diagnostics and digital health. This database has ten categories of investors ranging from angel groups and family offices to VCs, PEs, Big Pharma/Medtech, foundations and the non-dilutive federal, state and regional agencies.

The LSN mantra to healthcare scientist-entrepreneurs and fundraising CEOs is that partnering is a numbers game, and that getting a Global Target List (GTL) of potential partners that are a fit for your stage of development and product set is a crucial step to a successful fundraising campaign. Furthermore, it’s essential to canvass outside your region, engaging global partners to maximize the likelihood of building a relationship that could secure a partnership. 

The LSN Investor Research Team curates the LSN Investor Database, which consists of profiles that fundraising clients can access with an annual subscription. Tools like the database are essential aids for success in a global fundraising campaign. The database features more than ten thousand investor contacts representing several thousand funding and licensing firms. The team’s goal is to keep all the partnering mandates updated in order to ensure the best fit, and this is done through bi-annual interviews. 

These firms are willing to be part of the LSN Investor Platform because we provide them with quality deal-flow, companies that know they are a fit for the firm’s investment theme or partnering interests. Additionally, each year, five Redefining Ealy Stage Investments (RESI) partnering events attract the who’s-who of early-stage life science investing and give them another avenue to connect with fundraising companies that match their interests. These conferences consist of investor panels, workshops, and matched partnering meetings, taking advantage of the profiles the investor research team gathers and the long-term relationships we build while keeping their mandates current.  

The relationship between LSN and the global investor community is deep and has helped hundreds of companies get funded by connecting with investors and partners. Just this week, the Investor Research Team has updated over forty-five mandates, facilitating super fresh profile updates for LSN clients seeking funding. Check out this week’s investor mandates and reach out to your LSN business development representative to view these investors and learn how to get plugged into the LSN partnering ecosystem.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada 
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Ashley Zborowski
Director of Business Development
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!

Starting with Pep: An Early-Stage Conversation with Creative Bio-Peptides

8 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Creative Bio-Peptides is an early-stage company, founded and led by Dr. Michael Ruff, with a mission to improve lives through developing oral receptor-active peptides targeting neurodegenerative diseases. We spoke with Chief Business Officer, Michael Simon about the early-stage journey of Creative Bio-Peptides – how it was started, what their strategy looks like today, and where they see the company going forward.

Creative Bio-Peptides is a past participant at an Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by April 9 to save $100 on super early bird rates.

Digital RESI June Super Early Bird Ends Tomorrow

8 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Digital Redefining Early Stage Investments (RESI), June 8-10, is around the corner, which means that super early bird rates end tomorrow! Sign up by Friday, April 9 to save $100 on registration to take advantage of the RESI partnering system which enables early-stage fundraising executives to source investors and strategic partners based on a fit for their product and stage of development.

Digital RESI June also offers a variety of investor panels, educational workshops, and the Innovator’s Pitch Challenge – all designed to offer valuable insight to entrepreneurs and opportunities to make matches, build relationships, and cut deals. Digital RESI has been a part of hundreds of companies’ early-stage fundraising success stories. Sign up to save and make it a part of yours!

Innovator’s Pitch Challenge: Now Accepting Applications!

1 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI June is fast approaching, and is now accepting applications to the Innovator’s Pitch Challenge (IPC)! The sessions take place virtually June 8-10. IPC applications are now open until Friday, May 14.

The IPC is a virtual pitch experience in which participating companies receive a dedicated webpage accessible via the event live agenda, as well as the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services.

ARJUNA Therapeutics CEO, Ross Breckenridge said of the March Innovator’s Pitch Challenge:

I’m really happy to have participated in RESI and the IPC format. The investors were predominantly stage-and sector-appropriate for a biotech start up (not always the case in meetings like this). The IPC format was helpful in that we were able to post a short pitch online for on-demand viewing as well as having a ‘live’ discussion. Several of the panelists met with me after the panel, and I’ve been contacted by one investor (so far) outside the meeting after they’d seen the video pitch. I’m happy to recommend this meeting and the IPC format for early-stage biotech companies-I think this was money and time well spent for us.

Selected companies pay their registration, as well as an additional pitching fee, so apply before April 9 to save on super early bird rates! BrainXell CEO, Shouming Du also said of his experience in March:

I have had a very positive experience at RESI, my first time. Workshop, panel discussion, and IPC are complementary to each other. I like IPC format, posting materials in advance and focusing on live discussion in 10 minutes. I feel the extra money I spent on IPC is worth it, not just exposure or those 10 min Q&A. It has forced me to prepare relevant materials.

Thrive Bioscience CEO, Co-Founder & Board Director, Thomas Forest Farb-Horch won Digital RESI March’s IPC, and reached out to the RESI team to share his experience:

The quality of the judges and questions in the four Pitch Challenges were phenomenal. Panels were phenomenal, and I really enjoyed being on the Tools panel. Tad Weems and the other panelists did a fantastic job…My companies received lots of good leads and have lots of work to do, still following up.

Check out Thrive Bioscience’s sample dedicated webpage and apply for the Digital RESI June IPC by May 14!


1 Apr

85 Israeli Companies Present Breakthrough Medical Device and Digital Health Technologies to Global Industry Leaders

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN) and the Israel Export Institute have been working together for the last several years to build a stronger connection between LSN’s global network and the flourishing Israeli startup ecosystem. LSN is pleased to serve as an anchor partner to the Israel Export Institute’s upcoming event, MEDinISRAEL, taking place April 20-21. Read below to learn more about this event!

The 6th Biennial MEDinISRAEL Conference and Exhibition, Israel’s leading medical device and digital health event, will be held virtually April 20-21, 2021. The event will feature Israel’s leading medical device and digital health companies and host healthcare community members and experts from around the globe. The conference will address the issues of the digital future of healthcare, global opportunities in healthcare, the shift in point-of-care, hospital at home and telemedicine, private sector investments in the future of digital health, harnessing AI and data, the consumerization of health care and many more. The much-anticipated MEDinISRAEL 2021 will host key decision-makers and executives who generate thousands of business interactions with the global healthcare community, notable experts, leading hospitals, distributors, investors, and corporate members.

COVID-19 has created a tremendous challenge for the medical industry, and innovation is the key factor in meeting those challenges. The Israeli medical landscape represents a broad spectrum of companies that offer various medical products and technologies, making Israel an important global medical innovation hub. MEDinISRAEL will showcase innovative breakthroughs and new medical technologies through a Virtual Exhibition of 85 state-of-the-art Israeli medical device and digital health companies. Through and with the help of economic attachés of the Foreign Trade Administration at the Ministry of Economy, the Israeli companies will participate in hundreds of pre-qualified one-on-one meetings  with senior decision-makers in leading companies (e.g. Philips, TEVA, INSIGHTEC, EarlySense, TytoCare, Bioview, and many more).

The event will include the OpenMED Innovation Competition by Sanara Ventures, a pitch contest celebrating visionary achievements from the very best Israeli innovators focusing on digital health, bio-convergence, and medical device technologies. A variety of panels with world-class speakers will discuss the latest topics in the industry and trends in the post-pandemic era and share their best practices in health and care delivery to build healthier societies.

MEDinISRAEL’s speakers will include:

  • Frans van Houten, CEO, Philips, The Netherlands
  • John D. Halamka, MD, M.S., President, Mayo Clinic Platform, NY, USA
  • Harold F. Wolf, President & CEO, HIMSS, USA
  • Michael J. Dowling, President & CEO, Northwell Health, NY, USA
  • Ran D Balicer, MD, PhD, MPH, Founding Director, Clalit Research Institute; Chief Innovation Officer & Director, Innovation Division, Clalit Health Services, Israel
  • Arnon Afek, Associate Director-General & Acting Director, Sheba General Hospital; Chairman, Department of Medical Administration, Sheba Medical Center, Israel

“Israel has been blessed with a prospering and diverse healthcare ecosystem with more than 1,600 life science companies. The healthcare ecosystem is driven by Israeli entrepreneurship spirit, ongoing collaborations between academic institutes and the healthcare industry, governmental support tools, and one of the most efficient healthcare systems in the world. These factors, alongside with 25 years of expertise in implementing Health IT, electronic medical records, and Big Data Analytics have made Israel a center of attraction to the world’s leading companies and investors. MEDinISRAEL provides an opportunity to explore business opportunities and be informed about the current trends from healthcare experts from around the world, as we showcase Israeli models of advanced technologies, research and innovation.”

  • Ohad Cohen, Head, Foreign Trade Administration, Ministry of Economy & Industry

“We are proud and excited to host the world’s leading healthcare and business community members on our virtual event. In the course of two inspiring days, we will take a firsthand look at outstanding achievements, understand potential breakthroughs, witness productive collaborations, and explore the most innovative and state-of-the-art healthcare technologies coming from Israel. Especially nowadays, when a COVID-19 is challenging us all to create better and more efficient solutions, It is essential to keep pushing innovative minds into creating new health technologies. Israel is a major global player in the fight against the corona virus, and the Israeli companies are leading the changes in the healthtech field, structuring the digital acceleration. we anticipate thousands of visitors from around the world to join us, be part of this event, and create new business interactions which will lead to real business opportunities in the near future. MEDinISRAEL, alongside additional activities generated by IEI, continues to be the main on-the-ground platform for doing business with Israel’s medical device & digital health industry”.

  • Adiv Baruch, Chairman, Israel Export institute

MEDinISRAEL is initiated and produced by the Israeli Export Institute, in cooperation with the Foreign Trade Administration at the Ministry of Economy and Industry, the Ministry of Health, the Ministry of Foreign Affairs, and Healthcare Israel. MEDinISRAEL is partnering with a number of distinguished anchor of the Israeli Healthcare System and Digital Health Industry including, PHILIPS, Sanara Ventures, the Israel Innovation Authority Tel Aviv Sourasky Medical Center (Ichilov), Ramban Healthcare Campus, The Chaim Sheba Medical Center, Clalit Healthcare Services, Maccabi Healthcare Services, Merage Institute, and Life Science Nation (LSN).

For more information about MEDinISRAEL 2021, please visit:

Media Contact: Liron Hadar, Director, International Public Relations, Israel Export Institute

+972(3)5142942 / +972(54)3195654 /

Negotiating Term Sheets: A Hot Topic for Fundraising Entrepreneurs

1 Apr

By Gregory Mannix, Vice President International Business Development, LSN

At last month’s Healthtech Partnering Week, McDermott Will & Emery hosted a workshop focused on the all-important Term Sheet. A stellar panel of experts shared their own vast experience in this area, not only from a legal perspective, but from the perspective of a fundraising entrepreneur and an investor. Not surprisingly, this was among the best-attended panels at RESI, therefore, we are sharing the recording with our extended community.

If you have any questions about Term Sheets, feel free to reach out to MWE’s Angus McQuilken.

Nancy Briefs, President & CEO, AltrixBio, Inc.

Nancy-BriefsStrategic business leader with extensive experience creating value, driving strategy and launching product commercialization in diverse life science companies. Deep general management and fundraising expertise having raised over $500 M in equity including IPO. Innovative, collaborative and entrepreneurial, strong communicator and tenacious. Energized by turning innovation into commercial reality, working with creative scientists, and communicating value to partners and investors.

David Hendren, Managing Director, Augmentum Ventures

1602694001824David Hendren has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, biomedical technology, digital health, and related technology and service areas. He has deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel. David has led, co-invested and executed deals with leading firms and strategics, with exits including IPO, M&A, and technology licensing transactions. In operating, board, and advisory roles, David has been central to identifying opportunity, building teams, formulating strategy, securing capital, developing business and strategic alliances, and driving successful exits to harvest value for stakeholders.

John Demeter, General Counsel, Khosla Ventures

John-DemeterJohn is the General Counsel at Khosla Ventures. He joined Khosla in 2016 and has been working with investors and entrepreneurs since 2007. Prior to joining Khosla, John spent nine years at WilmerHale where he represented investors and entrepreneurs in hundreds of financing and acquisition transactions. Given his experience, John has also served as an adjunct professor and guest lecturer at numerous Bay Area law schools on the topic of venture capital transactions.

Prior to attending law school, John held sales and marketing positions at two Bay Area venture-backed companies, had an ever so brief career in local radio, and spent a year working at his family’s commercial transportation business.

John received CORe certification from Harvard Business School Online, his JD cum laude from University of San Francisco School of Law and his Bachelor of Arts in Communications from Boston College. A Bay Area native, John is passionate about the local sports teams. He lives in San Francisco with his wife, four young children and loyal pack of dogs.

Mark Mihanovic, Partner, McDermott Will & Emery

Mark-J.-MihanovicMark J. Mihanovic, head of the Firm’s California Corporate group and head of the Emerging Companies/Venture Capital group, focuses his practice primarily in the areas of corporate finance and mergers and acquisitions. He represents companies in a broad range of industries, with a particular emphasis on technology, life science and health care companies. Mark serves as corporate liaison partner in the Firm’s strategic alliance with MWE China Law Offices based in Shanghai. Mark serves as lead counsel on behalf of issuers and underwriters in public offerings and private placements (including private investments in public equities (PIPEs)) of equity and debt securities. He handles stock and asset acquisitions, divestitures, mergers, proxy fights and joint ventures and has had primary oversight responsibility for the regional and worldwide acquisition programs of multiple clients. Mark represents early-stage companies in connection with formation and organizational issues and venture capital and other financings and has also represented investors in complex venture capital transactions involving equity and debt. Mark has substantial experience advising corporate boards of directors and management regarding fiduciary duties (including in connection with potential change in control transactions and consideration of “poison pill” stockholders rights plans) and corporate governance issues. He assists publicly traded companies with their Securities and Exchange Commission filings and other securities compliance matters. He also advises investment banks on securities compliance issues and in acting as financial adviser and delivering fairness opinions in the context of acquisitions and restructurings.

Aroma Sharma, Partner, McDermott Will & Emery

1517735011203Aroma Sharma focuses her practice on a wide range of corporate and transactional matters, acting predominantly for private and emerging companies. Aroma has advised clients on mergers and acquisitions, debt and equity financing, corporate and equity restructuring and recapitalizations and joint ventures in various industries, including technology and health and life sciences. She also advises clients regularly on general corporate and corporate governance matters. Aroma also has experience working on cross-border transactions, including business’ international expansion into new territories.

Aroma regularly serves as primary outside counsel for clients. She understands the importance of knowing a client’s business, and completed a secondment with a large, multi-national accounting and advisory firm, assisting with drafting and negotiating commercial transactional agreements.

Aroma was also a fellow in Entrepreneurship, Social Entrepreneurship & Innovation at NYU School of Law and has a special interest in working with social enterprises and sustainable businesses.

Digital RESI June – Agenda Announced!

25 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


It has been over a year since Life Science Nation (LSN) started organizing virtual conferences, which has been met with overwhelming support from the community of investors, service providers, and early-stage companies within life science and healthcare. Thank you to all who have supported LSN throughout the past year!

LSN is pleased to announce the newest, 3-day Digital RESI conference, June 8-10. Check out the agenda below!

Digital RESI June Agenda

June 8
June 9
June 10
10:00amCorporate Venture Capital
The Corporate Landscape Morphed & New Opportunities Abound
Angel Investors
Explaining the Process of Engagement
Medtech Strategics
Large Medical Device Firms Seeking External Innovation
12:00pmInnovator’s Pitch Session #1Innovator’s Pitch Session #3Innovator’s Pitch Session #5
2:00pmImpact Investors
Life Science Investors Looking for More Than Financial Returns
Family Offices
How Do Family Offices View Seed & Series A Rounds?
Big Pharma
Pipeline Strategy for Preclinical and Early Clinical Assets
3:00pmInnovator’s Pitch Session #2Innovator’s Pitch Session #4Innovator’s Pitch Session #6

Each panel is held live during the conference and will feature active investors and strategic partners as participants sharing their insights and offering helpful tips to fundraising executives.

Digital RESI June will also feature the Innovator’s Pitch Challenge (IPC) – the virtual pitch experience in which participating companies receive a dedicated webpage accessible via the event live agenda, as well as the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services. These sessions provide valuable insights and feedback to help companies improve their skills, as well as build connections in a valuable setting.

IPC applications are now open until Friday, May 14. Selected companies pay their registration, as well as an additional pitching fee, so apply before April 9 to save on super early bird rates!

%d bloggers like this: